Startup of the Week: Captain Brew Coffee redefines ready-to-drink beverages

Updated 05 March 2019
0

Startup of the Week: Captain Brew Coffee redefines ready-to-drink beverages

Cold brew fans can now enjoy a new brand in the market. Captain Brew Coffee was set up and launched last autumn by Mohammed Sabbagh, a 37-year-old engineer from Saudi Arabia.

“It is intended to redefine the cold brew, ready-to-drink beverages in the region,” Sabbagh told Arab News.

He explained that the concept emerged in Jeddah’s Medd Cafe and Roastery and that the packaging idea also came about that same day, with the help of Medd’s Mohammed Hashani. It was decided after much brainstorming that the packaging should be like beer bottles.

“The labels were created by the designer Shahad Nazer. Her creativity and designs brought the product to life and, with the ideas I provided, she transformed the bottles.”

The range started with two flavors — original and coconut — and received positive feedback.

The support encouraged him to debut the product in Jeddah’s Homegrown Market, just 23 days from when the idea was conceptualized.

“On launch day we sold quite a few bottles and gathered feedback from those who tasted the first two products. Some of the feedback received was that the bottle size was too big and the price was slightly high. As a result we responded by introducing our standardized size of 250ml with optimized pricing.” 

More flavors came along — Roko Berry and Arabicolada — while the latest creation was inspired by a cultural festival. 

“My most recent flavor is Peachula. Its label design drew inspiration from the Al Ula balloon festival that took place during Winter at Tantora. We use fresh organic coffee beans from Medd. The ground specialty coffee is soaked in water for 21 hours at a cool temperature. 

“Our coffee blends are premium and from various regions including Yemen and Ethiopia. The water used is bottled with low sodium, and the flavors are all natural.”

Captain Brew Coffee products can be found in many places in Jeddah such as Sofa Lounge, Arty Cafe, Juice Container and The Sandwich Gallery.

The brand took part in a number of public events including International Coffee Week last November and concerts held at King Abdullah Economic City.

“Captain Brew Coffee is planning to introduce a smaller size bottle that will target the mass market and be focused toward modern trade markets with a longer shelf life and more competitive pricing scheme.”

Keep up with Captain Brew Coffee on Instagram: @captainbrewcoffee


Jazz Pharma’s sleep disorder treatment gets US FDA nod

Updated 21 March 2019
0

Jazz Pharma’s sleep disorder treatment gets US FDA nod

  • The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea
  • The patent of Jazz's narcolepsy drug, Xyrem, were declared invalid by a US appeals court in July
The US Food and Drug Administration approved Jazz Pharmaceuticals Plc’s treatment for patients with a form of sleep disorder, the company said on Wednesday.
The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).
Solriamfetol is expected to be commercially available in the United States following the final scheduling decision by the Drug Enforcement Administration (DEA), Jazz said in a statement.
The approval comes as Jazz is trying to reduce its reliance on its blockbuster narcolepsy drug, Xyrem, whose patents were declared invalid by a US appeals court in July.
Xyrem is an approved treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy. It brought in sales of $1.4 billion in 2018 and accounted for about 70 percent of company’s revenue.
“Jazz is trying to reduce its reliance on Xyrem, and solriamfetol will be one of the drugs it plans to launch to do that,” Mizuho Securities USA analyst Irina Koffler said ahead of the agency’s decision.
“Solriamfetol is expected to be an important driver of both diversification and growth,” RBC Capital Markets analyst Randall Stanicky said in a note ahead of the approval.
Solriamfetol is expected to bring in revenue of $314 million by 2024, Stanicky said.
Narcolepsy is a chronic sleep disorder with overwhelming daytime drowsiness and sudden attacks of sleep, while obstructive sleep apnea is a potentially serious sleep disorder that can cause breathing to repeatedly stop and start.
“Narcolepsy is very disabling to people as they often get diagnosed young and stop their education and drop out of high school or college,” Koffler said.
“Sleep apnea is a different problem in the sense that a lot of people don’t know they have it, have trouble breathing at night and they even fall asleep during the day.”